2006
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 2006, 43: 1089-1134. PMID: 17029130, DOI: 10.1086/508667.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyHuman granulocytic anaplasmosisDiseases SocietyLyme diseasePost-Lyme disease syndromeGranulocytic anaplasmosisPrevious treatment guidelinesManagement of patientsClinical practice guidelinesEvidence-based guidelinesHealth care providersTickborne infectionTreatment guidelinesClinical manifestationsAntimicrobial therapyClinical assessmentPractice guidelinesCare providersDisease syndromeExpert panelDiseasePreventionPatientsTherapyInfection
1994
Pneumococcal Vaccine After 15 Years of Use: Another View
Fedson D, Shapiro E, LaForce F, Mufson M, Musher D, Spika J, Breiman R, Broome C. Pneumococcal Vaccine After 15 Years of Use: Another View. JAMA Internal Medicine 1994, 154: 2531-2535. DOI: 10.1001/archinte.1994.00420220021003.Commentaries, Editorials and LettersPneumococcal vaccineYears of useInfectious Diseases SocietyWorld Health Organization Regional OfficeAdvisory CommitteePneumococcal vaccinationDiseases SocietyVaccine effectivenessRetrospective studyVaccine trialsClinical effectivenessAmerican CollegeElderly populationOngoing critical reviewVaccineAvailable evidenceNational Advisory CommitteeTechnical Advisory GroupImmunizationAdvisory GroupTask ForceUnited StatesConclusive evidenceGroupEvidence